Antiangiogenic tumor therapy

BioTechniques

Volumn 34, Issue 5, 2003, Pages 1048-1063

  Davis, Darren W ^a   McConkey, David J ^a   Zhang, Wei ^a   Herbst, Roy S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; CILENGITIDE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; ENDOSTATIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FUMAGILLOL CHLOROACETYLCARBAMATE; GEFITINIB; IMATINIB; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; N ACETYLCOLCHINOL PHOSPHATE; ONCOPROTEIN; PLATELET DERIVED GROWTH FACTOR B; TANOMASTAT; TEMOZOLOMIDE; THALIDOMIDE; TRANSFORMING GROWTH FACTOR ALPHA; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CALORIMETRY; CANCER; CANCER INHIBITION; DRUG EFFICACY; HUMAN; NONHUMAN; NOTE; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

EID: 0037990077     PISSN: 07366205     EISSN: None     Source Type: Journal    
DOI: 10.2144/03345dd01     Document Type: Note

References (100)

1. Carmeliet, P. 2000. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 6:389-395.
2. Folkman, J. 1971. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285:1182-1186.
3. White, C.W., H.M. Sondheimer, E.C. Crouch, H. Wilson, and L.L. Fan. 1989. Treatment of pulmonary hemangiomatosis with recombinant interferon α-2a. N. Engl. J. Med. 320:1197-1200.
4. Figg, W.D., J.M. Pluda, R.M. Lush, M.W. Saville, K. Wyvill, E. Reed, and R. Yarchoan. 1997. The pharmacokinetics of TNP-470, a new angiogenesis inhibitor. Pharmacotherapy 17:91-97.
5. Folkman, J. 1995. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1:27-31.
6. Yancopoulos, G.D., S. Davis, N.W. Gale, J.S. Rudge, S.J. Wiegand, and J. Holash. 2000. Vascular-specific growth factors and blood vessel formation. Nature 407:242-248.
7. Boehm, T., J. Folkman, T. Browder, and M.S. O'Reilly. 1997. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404-407.
8. Kerbel, R.S. 1997. A cancer therapy resistant to resistance. Nature 390:335-336.
9. Kaban, L.B., J.B. Mulliken, R.A. Ezekowitz, D. Ebb, P.S. Smith, and J. Folkman. 1999. Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon α-2a. Pediatrics 103:1145-1149.
10. O'Reilly, M.S., L. Holmgren, C. Chen, and J. Folkman. 1996. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 2:689-692.
11. Bold, G., K.H. Altmann, J. Frei, M. Lang, P.W. Manley, P. Traxler, B. Wietfeld, J. Bruggen, et al. 2000. New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. J. Med. Chem. 43:2310-2323.
12. Relf, M., S. LeJeune, P.A. Scott, S. Fox, K. Smith, R. Leek, A. Moghaddam, R. Whitehouse, et al. 1997. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 57:963-969.
13. Keck, P.J., S.D. Hauser, G. Krivi, K. Sanzo, T. Warren, J. Feder, and D.T. Connolly. 1989. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246:1309-1312.
14. Bruns, C.J., M.T. Harbison, D.W. Davis, C.A. Portera, R. Tsan, D.J. McConkey, D.B. Evans, J.L. Abbruzzese, et al. 2000. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin. Cancer Res. 6:1936-1948.
15. Inoue, K., J.W. Slaton, D.W. Davis, D.J. Hicklin, D.J. McConkey, T. Karashima, R. Radinsky, and C.P. Dinney. 2000. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin. Cancer Res. 6:2635-2643.
16. Ozawa, S., H. Shinohara, H.O. Kanayama, C.J. Bruns, C.D. Bucana, L.M. Ellis, D.W. Davis, and I.J. Fidler. 2001. Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferon-α. Neoplasia 3:154-164.
17. Ciardiello, F. and G. Tortora. 2001. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res. 7:2958-2970.
18. Kerbel, R.S., J. Yu, J. Tran, S. Man, A. Viloria-Petit, G. Klement, B.L. Coomber, and J. Rak. 2001. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev. 20:79-86.
19. Kerbel, R. and J. Folkman. 2002. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2:727-739.
20. Ullrich, A., L. Coussens, J.S. Hayflick, T.J. Dull, A. Gray, A.W. Tam, J. Lee, Y. Yarden, et al. 1984. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309:418-425.
21. Baselga, J., D. Tripathy, J. Mendelsohn, S. Baughman, C.C. Benz, L. Dantis, N.T. Sklarin, A.D. Seidman, et al. 1999. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin. Oncol. 26:78-83.
22. Vogel, C.L., M.A. Cobleigh, D. Tripathy, J.C. Gutheil, L.N. Harris, L. Fehrenbacher, D.J. Slamon, M. Murphy, et al. 2001. First-line Herceptin monotherapy in metastatic breast cancer. Oncology 61 Suppl 2:37-42.
23. Persons, D.L., M.M. Bui, M.C. Lowery, H.F. Mark, J.F. Yung, J.M. Birkmeier, E.Y. Wong, S.J. Yang, et al. 2000. Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: a multicenter portability study. Ann. Clin. Lab. Sci. 30:41-48.
24. de Bono, J.S. and E.K. Rowinsky. 2002. The ErbB receptor family: a therapeutic target for cancer. Trends Mol. Med. 8:S19-S26.
25. Albanell, J., F. Rojo, S. Averbuch, A. Feyereislova, J.M. Mascaro, R. Herbst, P. LoRusso, D. Rischin, et al. 2002. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J. Clin. Oncol. 20:110-124.
26. Baselga, J., D. Rischin, M. Ranson, H. Calvert, E. Raymond, D.G. Kieback, S.B. Kaye, L. Gianni, et al. 2002. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol. 20:4292-4302.
27. Herbst, R.S., A.M. Maddox, M.L. Rothenberg, E.J. Small, E.H. Rubin, J. Baselga, F. Rojo, W.K. Hong, et al. 2002. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J. Clin. Oncol. 20:3815-3825.
28. Ranson, M., L.A. Hammond, D. Ferry, M. Kris, A. Tullo, P.I. Murray, V. Miller, S. Averbuch, et al. 2002. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J. Clin. Oncol. 20:2240-2250.
29. Albanell, J., F. Rojo, and J. Baselga. 2001. Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. Semin. Oncol. 28:56-66.
30. Bernatchez, P.N., S. Soker, and M.G. Sirois. 1999. Vascular endothelial growth factor effect on endothelial cell proliferation, migration, and plateletactivating factor synthesis is Flk-1-dependent. J. Biol. Chem. 274:31047-31054.
31. Hubbard, S.R. 1999. Structural analysis of receptor tyrosine kinases. Prog. Biophys. Mol. Biol. 71:343-358.
32. Millauer, B., S. Wizigmann-Voos, H. Schnurch, R. Martinez, N.P. Moller, W. Risau, and A. Ullrich. 1993. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72:835-846.
33. Quinn, T.P., K.G. Peters, C. De Vries, N. Ferrara, and L.T. Williams. 1993. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc. Natl. Acad. Sci. USA 90:7533-7537.
34. Millauer, B., L.K. Shawver, K.H. Plate, W. Risau, and A. Ullrich. 1994. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367:576-579.
35. Kuenen, B.C., L. Rosen, E.F. Smit, M.R. Parson, M. Levi, R. Ruijter, H. Huisman, M.A. Kedde, et al. 2002. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J. Clin. Oncol. 20:1657-1667.
36. Stopeck, A., M. Sheldon, M. Vahedian, G. Cropp, R. Gosalia, and A. Hannah. 2002. Results ofa phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin. Cancer Res. 8:2798-2805.
37. Chambers, A.F. and L.M. Matrisian. 1997. Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst. 89:1260-1270.
38. Liotta, L.A. and W.G. Stetler-Stevenson. 1990. Metalloproteinases and cancer invasion. Semin. Cancer Biol. 1:99-106.
39. Murray, G.I., M.E. Duncan, P. O'Neil, W.T. Melvin, and J.E. Fothergill. 1996. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat. Med. 2:461-462.
40. Rowinsky, E.K., R. Humphrey, L.A. Hammond, C. Aylesworth, L. Smetzer, M. Hidalgo, M. Morrow, L. Smith, et al. 2000. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. J. Clin. Oncol. 18:178-186.
41. Shepherd, F.A., G. Giaccone, L. Seymour, C. Debruyne, A. Bezjak, V. Hirsh, M. Smylie, S. Rubin, et al. 2002. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J. Clin. Oncol. 20:4434-4439.
42. Levitt, N.C., F.A. Eskens, K.J. O'Byrne, D.J. Propper, L.J. Denis, S.J. Owen, L. Choi, J.A. Foekens, et al. 2001. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MM1270 (CGS27023A), in patients with advanced solid cancer. Clin. Cancer Res. 7:1912-1922.
43. Rudek, M.A., W.D. Figg, V. Dyer, W. Dahut, M.L. Turner, S.M. Steinberg, D.J. Liewehr, D.R. Kohler, et al. 2001. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J. Clin. Oncol. 19:584-592.
44. Herbst, R.S., T.L. Madden, H.T. Tran, G.R. Blumenschein, Jr., C.A. Meyers, L.F. Seabrooke, F.R. Khuri, V.K. Puduvalli, et al. 2002. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. J. Clin. Oncol. 20:4440-4447.
45. O'Reilly, M.S. 2002. The combination of antiangiogenic therapy with other modalities. Cancer J. 8(Suppl 1):S89-S99.
46. Brewer, G.J., R.D. Dick, D.K. Grover, V. LeClaire, M. Tseng, M. Wicha, K. Pienta, B.G. Redman, et al. 2000. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: phase I study. Clin. Cancer Res. 6:1-10.
47. Simon, R., B. Freidlin, L. Rubinstein, S.G. Arbuck, J. Collins, and M.C. Christian. 1997. Accelerated titration designs for phase I clinical trials in oncology. J. Natl. Cancer Inst. 89:1138-1147.
48. Herbst, R.S., A.T. Lee, H.T. Tran, and J.L. Abbruzzese. 2001. Clinical studies of angiogenesis inhibitors: the University of Texas MD Anderson Center trial of human endostatin. Curr. Oncol. Rep. 3:131-140.
49. Herbst, R.S., N.A. Mullani, D.W. Davis, K.R. Hess, D.J. McConkey, C. Charnsangavej, M.S. O'Reilly, H.W. Kim, et al. 2002. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J. Clin. Oncol. 20:3804-3814.
50. Braybrooke, J.P., K.J. O'Byrne, D.J. Propper, A. Blann, M. Saunders, N. Dobbs, C. Han, J. Woodhull, et al. 2000. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Clin. Cancer Res. 6:4697-4704.
51. Mancuso, P., A. Burlini, G. Pruneri, A. Goldhirsch, G. Martinelli, and F. Bertolini. 2001. Resting and activated endothelial cells are increased in the peripheral blood ofcancer patients. Blood 97:3658-3661.
52. Lyden, D., K. Hattori, S. Dias, C. Costa, P. Blaikie, L. Butros, A. Chadburn, B. Heissig, et al. 2001. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7:1194-1201.
53. Rafii, S., D. Lyden, R. Benezra, K. Hattori, and B. Heissig. 2002. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat. Rev. Cancer 2:826-835.
54. Rademacher, A., M. Paulitschke, R. Meyer, and R. Hetzer. 2001. Endothelialization of PTFE vascular grafts under flow induces significant cell changes. Int. J. Artif. Organs 24:235-242.
55. Lee, K.H. 2001. Proteomics: a technology-driven and technology-limited discovery science. Trends Biotechnol. 19:217-222.
56. George, D. 2001. Platelet-derived growth factor receptors: a therapeutic target in solid tumors. Semin. Oncol. 28:27-33.
57. Ostman, A. and C.H. Heldin. 2001. Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv. Cancer Res. 80:1-38.
58. Pantazis, P., P.G. Pelicci, R. Dalla-Favera, and H.N. Antoniades. 1985. Synthesis and secretion of proteins resembling platelet-derived growth factor by human glioblastoma and fibrosarcoma cells in culture. Proc. Natl. Acad. Sci. USA 82:2404-2408.
59. Uehara, H., S.J. Kim, T. Karashima, D.L. Shepherd, D. Fan, R. Tsan, J.J. Killion, C. Logothetis, et al. 2003. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J. Natl. Cancer Inst. 95:458-470.
60. Shaheen, R.M., D.W. Davis, W. Liu, B.K. Zebrowski, M.R. Wilson, C.D. Bucana, D.J. McConkey, et al. 1999. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res. 59:5412-5416.
61. Mundhenke, C., J.P. Thomas, G. Wilding, F.T. Lee, F. Kelzc, R. Chappell, R. Neider, L.A. Sebree, et al. 2001. Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin. Clin. Cancer Res. 7:3366-3374.
62. Inoue, K., J.W. Slaton, P. Perrotte, D.W. Davis, C.J. Bruns, D.J. Hicklin, D.J. McConkey, P. Sweeney, et al. 2000. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin. Cancer Res. 6:4874-4884.
63. Davis, D.W., T.A. Buchholz, K.R. Hess, A.A. Sahin, V. Valero, and D.J. McConkey. 2003. Automated quantification ofapoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response. Clin. Cancer Res. 9:955-960.
64. St. Croix, B., C. Rago, V. Velculescu, G. Traverso, K.E. Romans, E. Montgomery, A. Lal, G.J. Riggins, et al. 2000. Genes expressed in human tumor endothelium. Science 289:1197-1202.
65. Kobayashi, T., M. Yamaguchi, S. Kim, J. Morikawa, S. Ogawa, S. Ueno, E. Suh, E. Dougherty, et al. 2003. Microarray reveals differences in both tumors and vascular specific gene expression in de novo CD5+ and CD5-diffuse large B-cell lymphomas. Cancer Res. 63:60-66.
66. Kohn, E.C., E. Reed, G.A. Sarosy, L. Minasian, K.S. Bauer, F. Bostick-Bruton, V. Kulpa, E. Fuse, et al. 2001. A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction. Clin. Cancer Res. 7:1600-1609.
67. Richardson, P.G., R.L. Schlossman, E. Weller, T. Hideshima, C. Mitsiades, F. Davies, R. LeBlanc, L.P. Catley, et al. 2002. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100:3063-3067.
68. Gutheil, J.C., T.N. Campbell, P.R. Pierce, J.D. Watkins, W.D. Huse, D.J. Bodkin, and D.A. Cheresh. 2000. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphav-beta3. Clin. Cancer Res. 6:3056-3061.
69. Brivio, F., P. Lissoni, F. Rovelli, A. Nespoli, F. Uggeri, L. Fumagalli, and G. Gardani. 2002. Effects of IL-2 preoperative immunotherapy on surgery-induced changes in angiogenic regulation and its prevention of VEGF increase and IL-12 decline. Hepatogastroenterology 49:385-387.
70. Baidas, S.M., E.P. Winer, G.F. Fleming, L. Harris, J.M. Pluda, J.G. Crawford, H. Yamauchi, C. Isaacs, et al. 2000. Phase II evaluation of thalidomide in patients with metastatic breast cancer. J. Clin. Oncol. 18:2710-2717.
71. Daliani, D.D., C.N. Papandreou, P.F. Thall, X. Wang, C. Perez, R. Oliva, L. Pagliaro, and R. Amato. 2002. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer 95:758-765.
72. Escudier, B., N. Lassau, D. Couanet, E. Angevin, F. Mesrati, S. Leborgne, A. Garofano, C. Leboulaire, et al. 2002. Phase II trial of thalidomide in renal-cell carcinoma. Ann. Oncol. 13:1029-1035.
73. Gutheil, J. and D. Finucane. 2000. Thalidomide therapy in refractory solid tumour patients. Br. J. Haematol. 110:754.
74. Figg, W.D., P. Arlen, J. Gulley, P. Fernandez, M. Noone, K. Fedenko, M. Hamilton, C. Parker, et al. 2001. A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Semin. Oncol. 28:62-66.
75. Short, S.C., D. Traish, A. Dowe, F. Hines, M. Gore, and M. Brada. 2001. Thalidomide as an anti-angiogenic agent in relapsed gliomas. J. Neurooncol. 51:41-45.
76. Heath, E.I., S. O'Reilly, R. Humphrey, P. Sundaresan, R.C. Donehower, S. Sartorius, M.J. Kennedy, D.K. Armstrong, et al. 2001. Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 48:269-274.
77. Bhargava, P., J.L. Marshall, W. Dahut, N. Rizvi, N. Trocky, J.I. Williams, H. Hait, S. Song, et al. 2001. A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers. Clin. Cancer Res. 7:3912-3919.
78. Galbraith, S.M., G.J. Rustin, M.A. Lodge, N.J. Taylor, J.J. Stirling, M. Jameson, P. Thompson, D. Hough, et al. 2002. Effects of 5,6-dimethylx-anthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J. Clin. Oncol. 20:3826-3840.
79. Eder, J.P., Jr., J.G. Supko, J.W. Clark, T.A. Puchalski, R. Garcia-Carbonero, D.P. Ryan, L.N. Shulman, J. Proper, et al. 2002. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J. Clin. Oncol. 20:3772-3784.
80. Herbst, R.S., K.R. Hess, H.T. Tran, J.E. Tseng, N.A. Mullani, C. Charnsangavej, T. Madden, D.W. Davis, et al. 2002. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. Oncol. 20:3792-3803.
81. Thomas, J.P., R.Z. Arzoomanian, D. Alberti, R. Marnocha, F. Lee, A. Friedl, K. Tutsch, A. Dresen, et al. 2003. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. Oncol. 21:223-231.
82. Turetschek, K., A. Preda, E. Floyd, D.M. Shames, V. Novikov, T.P. Roberts, J.M. Wood, Y. Fu, et al. 2002. MRI monitoring of tumor response to a novel VEGF tyrosine kinase inhibitor in an experimental breast cancer model. Acad. Radiol. 9(Suppl) 2:S519-S520.
83. Jayson, G.C., J. Zweit, A. Jackson, C. Mulatero, P. Julyan, M. Ranson, L. Broughton, J. Wagstaff, et al. 2002. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J. Natl. Cancer Inst. 94:1484-1493.
84. Gordon, M.S., K. Margolin, M. Talpaz, G.W. Sledge, Jr., E. Holmgren, R. Benjamin, S. Stalter, S. Shak, et al. 2001. Phase I safety and pharmaco-kinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 19:843-850.
85. Sandberg, J.A., V.P. Parker, K.S. Blanchard, D. Sweedler, J.A. Powell, A. Kachensky, L. Bellon, N. Usman, et al. 2000. Pharmacokinetics and tolerability of an antiangiogenic ribozyme (ANGIOZYME) in healthy volunteers. J. Clin. Pharmacol. 40:1462-1469.
86. Chen, H.X., R.E. Gore-Langton, and B.D. Cheson. 2001. Clinical trials referral resource: current clinical trials of the anti-VEGF monoclonal antibody bevacizumab. Oncology 15:1017-1026.
87. Kabbinavar, F., H.I. Hurwitz, L. Fehrenbacher, N.J. Meropol, W.F. Novotny, G. Lieberman, S. Griffing, and E. Bergsland. 2003. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 21:60-65.
88. Agarwala, S.S. and J.M. Kirkwood. 2003. Temozolomide in combination with interferon α-2b in patients with metastatic melanoma: a phase I dose-escalation study. Cancer 97:121-127.
89. Bier, H., K.A. Reiffen, I. Haas, and P. Stasiecki. 1995. Dose-dependent access of murine anti-epidermal growth factor receptor monoclonal antibody to tumor cells in patients with advanced laryngeal and hypopharyngeal carcinoma. Eur. Arch. Otorhinolaryngol. 252:433-439.
90. Schober, R., T. Bilzer, A. Waha, G. Reifenberger, W. Wechsler, A. von Deimling, O.D. Wiestler, M. Westphal, et al. 1995. The epidermal growth factor receptor in glioblastoma: genomic amplification, protein expression, and patient survival data in a therapeutic trial. Clin. Neuropathol. 14:169-174.
91. Robert, F., M.P. Ezekiel, S.A. Spencer, R.E Meredith, J.A. Bonner, M.B. Khazaeli, M.N. Saleh, D. Carey, et al. 2001. Phase I study of anti - epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J. Clin. Oncol. 19:3234-3243.
92. Gupta, A.K., W.G. McKenna, C.N. Weber, M.D. Feldman, J.D. Goldsmith, R. Mick, M. Machtay, D.I. Rosenthal, et al. 2002. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin. Cancer Res. 8:885-892.
93. Hidalgo, M., L.L. Siu, J. Nemunaitis, J. Rizzo, L.A. Hammond, C. Takimoto, S.G. Eckhardt, A. Tolcher, et al. 2001. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. 19:3267-3279.
94. OSI Pharmaceuticals, Genentech and Roche announce data from clinical studies of Tarceva. 2001. Expert Review of Anticancer Therapy 1:4-5.
95. Eckhardt, S.G., J. Rizzo, K.R. Sweeney, G. Cropp, S.D. Baker, M.A. Kraynak, J.G. Kuhn, M.A. Villalona-Calero, et al. 1999. Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors. J. Clin. Oncol. 17:1095-1104.
96. Ko, Y.J., E.J. Small, F. Kabbinavar, A. Chachoua, S. Taneja, D. Reese, A. DePaoli, A. Hannah, et al. 2001. A multi-institutional phase II study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. Clin. Cancer Res. 7:800-805.
97. Tulpule, A., D.T. Scadden, B.M. Espina, S. Cabriales, W. Howard, K. Shea, and P.S. Gill. 2000. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 18:716-723.
98. Batist, G., F. Patenaude, P. Champagne, D. Croteau, C. Levinton, C. Hariton, B. Escudier, and E. Dupont. 2002. Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. Ann. Oncol. 13:1259-1263.
99. AEterna reports on its phase II trial of neovastat. 2001. Expert Review of Anticancer Therapy 1:3-4.
100. Groen, H.J., E.G. de Vries, W. Wynendaele, W.T. van der Graaf, E. Fokkema, M.J. Lechuga, I. Poggesi, L.Y. Dirix, et al. 2001. PNU-145156E, a novel angiogenesis inhibitor, in patients with solid tumors: a phase I and pharmacokinetic study. Clin. Cancer Res. 7:3928-3933.